HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...
Arcus Biosciences (RCUS) announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer effective January 31, 2025. Dr.
M.D., Ph.D., incoming chief medical officer at Arcus Biosciences. "The company’s portfolio of molecules, most of which are being developed on top of the current standards of care, has the ...
Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that ...
M.D., Ph.D., incoming chief medical officer at Arcus Biosciences. “The company’s portfolio of molecules, most of which are being developed on top of the current standards of care, has ...
Arcus Biosciences named former Amgen executive Richard Markus as its chief medical officer. The biopharmaceutical company, which is focused on cancer treatments, said Tuesday that Markus is scheduled ...
Hayward, CA-based Arcus Biosciences, Inc. (NYSE ... Dr. Richard Markus has been named the new Chief Medical (TASE:PMCN) Officer (CMO), effective January 31, 2025. His appointment coincides with ...
Hayward, CA-based Arcus Biosciences, Inc. (NYSE ... Dr. Richard Markus has been named the new Chief Medical (TASE:PMCN) Officer (CMO), effective January 31, 2025. His appointment coincides with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback